Why is Peregrine Pharmaceuticals not going public with more Biomarker data now in regards to Precision For Medicine/Epiontis, which directly relates back to PS Targeting ....so why ?
The last time the CEO of PFM got a large block of money from Berkshire ....back in the UBC days they ended up selling out cheap so why do they PFM secure the rights to Epiontis and buy them out and Berkshire is back at it again.....
Why is Peregrine Pharmaceuticals not going public with the extended survival rates, MOS improvements with their Bavi patients and cross analyzing the Biomarker data and making it public now so a proper competitive bid which would allow better terms from possibly any other deal they may have been forced into ??
Market Data 
Markets 
AI
